Intercure (INCR) - Total Liabilities

Latest as of June 2025: ILA319.52 Million ILA ≈ $856.62K USD

Based on the latest financial reports, Intercure (INCR) has total liabilities worth ILA319.52 Million ILA (≈ $856.62K USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Intercure operating cash flow efficiency to assess how effectively this company generates cash.

Intercure - Total Liabilities Trend (2008–2024)

This chart illustrates how Intercure's total liabilities have evolved over time, based on quarterly financial data. Check Intercure asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Intercure Competitors by Total Liabilities

The table below lists competitors of Intercure ranked by their total liabilities.

Company Country Total Liabilities
Thai Textile Industry Public Company Limited
BK:TTI
Thailand ฿583.59 Million
Romsdal Sparebank
OL:ROMSB
Norway Nkr7.12 Billion
Iktinos Hellas S.A. Greek Marble Industry Technical and Touristic Company
AT:IKTIN
Greece €78.56 Million
Coventry Group Ltd
AU:CYG
Australia AU$205.48 Million
Candles Scandinavia AB Series B
ST:CANDLE-B
Sweden Skr254.05 Million
Wayi International Digital Entertainment Co
TWO:3086
Taiwan NT$31.83 Million
Cherrybro co.Ltd
KQ:066360
Korea ₩192.37 Billion
Pyung Hwa Ind
KO:090080
Korea ₩193.87 Billion

Liability Composition Analysis (2008–2024)

This chart breaks down Intercure's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see INCR company net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.85 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.74 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.43 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Intercure's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Intercure (2008–2024)

The table below shows the annual total liabilities of Intercure from 2008 to 2024.

Year Total Liabilities Change
2024-12-31 ILA364.90 Million
≈ $978.29K
+10.73%
2023-12-31 ILA329.55 Million
≈ $883.52K
-24.51%
2022-12-31 ILA436.53 Million
≈ $1.17 Million
+92.19%
2021-12-31 ILA227.13 Million
≈ $608.93K
+564.88%
2020-12-31 ILA34.16 Million
≈ $91.58K
+31.23%
2019-12-31 ILA26.03 Million
≈ $69.79K
+60.12%
2018-12-31 ILA16.26 Million
≈ $43.59K
+397.63%
2017-12-31 ILA3.27 Million
≈ $8.76K
-10.88%
2016-12-31 ILA3.67 Million
≈ $9.83K
+449.16%
2015-12-31 ILA667.52K
≈ $1.79K
-65.65%
2014-12-31 ILA1.94 Million
≈ $5.21K
-13.50%
2013-12-31 ILA2.25 Million
≈ $6.02K
-52.13%
2012-12-31 ILA4.69 Million
≈ $12.58K
-91.41%
2011-12-31 ILA54.64 Million
≈ $146.49K
+309.28%
2010-12-31 ILA13.35 Million
≈ $35.79K
+24.36%
2009-12-31 ILA10.73 Million
≈ $28.78K
-71.12%
2008-12-31 ILA37.17 Million
≈ $99.65K
--

About Intercure

TA:INCR Israel Drug Manufacturers - Specialty & Generic
Market Cap
$37.38 Million
ILA13.94 Billion ILA
Market Cap Rank
#22940 Global
#327 in Israel
Share Price
ILA255.00
Change (1 day)
+1.43%
52-Week Range
ILA228.00 - ILA585.00
All Time High
ILA6317.95
About

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in the biomed sector. The company has a strategic alliance with… Read more